Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck

Sandeep Samant, Michiel W. Van Den Brekel, Merrill S. Kies, Jim Wan, K. Thomas Robbins, David I. Rosenthal, Coen Rasch, Randal S. Weber

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50%) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 4-52 months). Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) rates at 5 years were 87%, 39%, and 61%, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck.

Original languageEnglish (US)
Pages (from-to)1263-1268
Number of pages6
JournalHead and Neck
Volume34
Issue number9
DOIs
StatePublished - Sep 1 2012

Fingerprint

Adenoid Cystic Carcinoma
Neck
Head
Cisplatin
Disease-Free Survival
Neoplasms
Oropharynx
Nasopharynx
Nasal Cavity
Carboplatin
Trachea
Tertiary Care Centers
Mouth
Survival Rate
Radiation
Neoplasm Metastasis
Survival

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

Samant, S., Van Den Brekel, M. W., Kies, M. S., Wan, J., Robbins, K. T., Rosenthal, D. I., ... Weber, R. S. (2012). Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head and Neck, 34(9), 1263-1268. https://doi.org/10.1002/hed.21905

Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. / Samant, Sandeep; Van Den Brekel, Michiel W.; Kies, Merrill S.; Wan, Jim; Robbins, K. Thomas; Rosenthal, David I.; Rasch, Coen; Weber, Randal S.

In: Head and Neck, Vol. 34, No. 9, 01.09.2012, p. 1263-1268.

Research output: Contribution to journalArticle

Samant, S, Van Den Brekel, MW, Kies, MS, Wan, J, Robbins, KT, Rosenthal, DI, Rasch, C & Weber, RS 2012, 'Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck', Head and Neck, vol. 34, no. 9, pp. 1263-1268. https://doi.org/10.1002/hed.21905
Samant S, Van Den Brekel MW, Kies MS, Wan J, Robbins KT, Rosenthal DI et al. Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. Head and Neck. 2012 Sep 1;34(9):1263-1268. https://doi.org/10.1002/hed.21905
Samant, Sandeep ; Van Den Brekel, Michiel W. ; Kies, Merrill S. ; Wan, Jim ; Robbins, K. Thomas ; Rosenthal, David I. ; Rasch, Coen ; Weber, Randal S. / Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck. In: Head and Neck. 2012 ; Vol. 34, No. 9. pp. 1263-1268.
@article{93d4456404de40eaa7c4364204f4791a,
title = "Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck",
abstract = "Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50{\%}) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 4-52 months). Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) rates at 5 years were 87{\%}, 39{\%}, and 61{\%}, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck.",
author = "Sandeep Samant and {Van Den Brekel}, {Michiel W.} and Kies, {Merrill S.} and Jim Wan and Robbins, {K. Thomas} and Rosenthal, {David I.} and Coen Rasch and Weber, {Randal S.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1002/hed.21905",
language = "English (US)",
volume = "34",
pages = "1263--1268",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck

AU - Samant, Sandeep

AU - Van Den Brekel, Michiel W.

AU - Kies, Merrill S.

AU - Wan, Jim

AU - Robbins, K. Thomas

AU - Rosenthal, David I.

AU - Rasch, Coen

AU - Weber, Randal S.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50%) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 4-52 months). Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) rates at 5 years were 87%, 39%, and 61%, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck.

AB - Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50%) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 4-52 months). Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) rates at 5 years were 87%, 39%, and 61%, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck.

UR - http://www.scopus.com/inward/record.url?scp=84864979667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864979667&partnerID=8YFLogxK

U2 - 10.1002/hed.21905

DO - 10.1002/hed.21905

M3 - Article

VL - 34

SP - 1263

EP - 1268

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 9

ER -